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NF-κB comprises a family of transcription factors that are critically involved in various inﬂammatory processes. In this paper,
the role of NF-κB in inﬂammation and atherosclerosis and the regulation of the NF-κB signaling pathway are summarized.
The structure, function, and regulation of the NF-κB inhibitors, IκBα and IκBβ, are reviewed. The regulation of NF-κB activity
by glucocorticoid receptor (GR) signaling and IκBα sumoylation is also discussed. This paper focuses on the recently reported
regulatory function that adipocyte enhancer-binding protein 1 (AEBP1) exerts on NF-κB transcriptional activity in macrophages,
in which AEBP1 manifests itself as a potent modulator of NF-κB via physical interaction with IκBα and a critical mediator of
inﬂammation.Finally,wesummarizetheregulatoryrolesthatrecentlyidentiﬁedIκBα-interactingproteinsplayinNF-κBsignaling.
Based on its proinﬂammatory roles in macrophages, AEBP1 is anticipated to serve as a therapeutic target towards the treatment of
various inﬂammatory conditions and disorders.
1. NF-κB SignalingPathway
The ability to sense external stimuli that could be lethal to
cells coupled with the potential to respond to such cytotoxic
signals by switching on defensive genes to sustain cell growth
and survival is a remarkable facet of nuclear factor kappa B
(NF-κB). Since NF-κB is ubiquitously expressed in almost all
types of cells and is a transcription factor that is sequestered
in an inactive state in the cytosol but can become activated
by a wide range of diverse internal and external stimuli, NF-
κB has long been considered an ideal safeguard to defend the
cell against countless stimuli and maintain its homeostasis
[1]. Moreover, NF-κB is a unique transcription factor in that
its function is not solely dependent on its expression when
needed. Rather, NF-κB is constitutively expressed in the cell,
butitdoesnotbecomeactiveuntilitiscalleduponforaction,
in which it will be ready and its mission can be accomplished
in a timely regulated fashion.
NF-κB comprises a family of ubiquitously expressed,
eukaryotic transcription factors that participate in the reg-
ulation of multiple immediate genes that are expressed at
the onset of many vital biological processes such as cell
growth, immunoregulation, apoptosis, and inﬂammation [2,
3]. Modulation of NF-κB activity can lead to many abnormal
cellular processes and diseases including asthma, arthritis,
atherosclerosis, obesity, and various types of cancers [2–7].
NF-κB exists in cells as a heterodimer of members of the
Rel family of proteins, including p50, p52, p65 (RelA), RelB,
and c-Rel, which share a high degree of structural similarity
(Figure 1).
2. Roles of NF-κB in Inﬂammation
and Atherosclerosis
One of the major functions of NF-κBi si t sk e yi n v o l v e m e n t
in inducing an eﬀective immune/inﬂammatory response
against viral and bacterial infections. The importance of NF-
κB role in initiating a potent inﬂammatory response cannot
be better signiﬁed than recognizing that the κBc o n s e n s u s
sequence is found in the promoter/enhancer regions of more2 Mediators of Inﬂammation
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Figure 1: Structural Organization of NF-κB/Rel and IκB Proteins.
(a) A schematic representation of some members of the Rel
family of proteins. Members of this family contain a unique,
highly conserved Rel homology domain (RHD) towards the N-
terminus, and this domain carries a nuclear localization signal
(NLS). Most members of the Rel family contain a C-terminally
locatedtransactivationdomain(TAD)thatisimportantforoptimal
transcriptional activity. RelB is a structurally unique member of
the NF-κB protein family in that it contains a leucine zipper-like
(LZ) region at its N-terminus. (b) A schematic representation of
some members of the IκB family of proteins, which are uniquely
characterized by the presence of 30-33-amino acid ankyrin (ANK)
repeats. At least for IκBα and IκBβ the most well-characterized
members of the IκB family, there are two conserved serine residues
at the N-terminus preceding the ﬁrst ANK repeat. Phosphorylation
of these two serine residues is known to be crucial for signaling
IκB proteins for ubiquitination and proteolytic degradation. At the
C-terminus of IκB proteins, there is a region rich with proline,
glutamate, serine, and threonine residues, and hence, it is named
the PEST domain. The number of amino acid residues within the
indicated proteins in mouse is shown.
than50diversegeneswhoseexpressionisknowntobecrucial
in driving an inﬂammatory response [8–10]. Inducible genes
thatareknowntobetransactivatedbyNF-κBinclude,butare
not limited to, IL-1β,I L - 6 ,I L - 8 ,T N F α,I F N γ,M C P - 1 ,i N O S ,
COX-2, intracellular adhesion molecule-1 (ICAM-1), and
vascular cell adhesion molecule-1 (VCAM-1) [2, 3, 10–19].
These molecules play critical roles in key biological events
involving cell recruitment, attachment, diﬀerentiation, pro-
liferation,andactivationconstitutinganactiveinﬂammatory
response.NF-κBisalsoknowntocooperatewithotheractive
transcription factors such as activator protein-1 (AP-1) in
upregulating the expression of some MMPs [20, 21], which
play destructive roles in atherosclerotic lesions rendering
them unstable and prone to rupture.
Genetic knockout models have provided lucid evi-
dence that NF-κB proteins are absolutely essential for
the development of a normal, eﬀective immune system,
since NF-κB genetic ablation, in general, renders mice
immunocompromised and prone to pathogenic infections.
Speciﬁcally, p50
−/− mice develop normally but are defec-
tive in immunoglobulin production, and thus, humoral
immune responses [22]. Likewise, p52
−/− mice develop
normally but their B-cell follicles and germinal centers do
not develop normally, and the mice are unable to launch
an adequate humoral response against T-cell-dependent
antigens[23,24].Althoughablationofp65causesembryonic
lethality due to liver apoptosis [25], ablation of TNFα or
TNFR rescues p65
−/− from the lethal phenotype [26, 27].
However, p65
−/−/TNFα
−/− mice are highly susceptible to
bacterialinfectionsandunabletoprovokeaninnateimmune
response. In addition, T and B lymphocytes of c-Rel
−/−
mice are unresponsive to various mitogenic stimuli, and the
mice are unable to generate a humoral immune response
[28]. Lastly, RelB
−/− mice are severely defective in generating
adaptive immune responses [29] .T h u s ,i ti se vi d e n tt h a tN F -
κB proteins are indispensable in generating eﬀective inﬂam-
matory, innate, and adaptive immune responses against viral
and bacterial pathogens.
The ﬁrst experimental evidence of NF-κBr o l ei n
atherosclerosis, a progressive inﬂammatory disease, came
from a study demonstrating that active NF-κBc a nb e
detected in aortae with evident atherosclerotic lesions but
not in normal, nonlesional aortae [30]. In fact, a strong
signal of active NF-κB can be detected in endothelial cells,
macrophages, and to a lesser extent, T lymphocytes within
atherosclerotic lesions [30, 31]. Interestingly, oxLDL is
potentially capable of activating NF-κB in endothelial cells
and macrophages in culture systems as well as in atheroscle-
roticlesions[32–35].Inthecontextofatherosclerosis,NF-κB
activation is believed to promote the expression of various
factors that mediate various processes such as proliferation,
chemotaxis, adhesion, inﬂammation, and thrombosis, key
events in atherogenesis [36]. Wolfrum and colleagues have
shown that mice which overexpress TNF-inducible protein
A20, a cytosolic zinc ﬁnger protein that inhibits NF-κBa c t i v -
ity by blocking IκB degradation, display signiﬁcantly smaller
atherosclerotic lesions compared to control mice [37]. A
recent study has clearly demonstrated that endothelium-
speciﬁc inhibition of NF-κB activity is accompanied by
signiﬁcant reduction in atherosclerotic lesion formation in
apolipoprotein E null (ApoE
−/−)m i c e[ 38]. In fact, inhibi-
tion of NF-κB leads to abrogated macrophage recruitment
to the atherosclerotic lesions and reduced expression of
cytokines and chemokines in the aortae of ApoE
−/− mice
[38]. Indeed, a large number of naturally occurring products
have been shown to attenuate the pathogenesis of atheroscle-
rosis by virtue of their ability to interfere with NF-κB
signaling [39–43]. Furthermore, several studies have demon-
strated a positive correlation between NF-κB activity and
incidenceofmyocardialinfarction[44–51].Duetoitscritical
role in atherosclerosis and myocardial infarction, NF-κBi s
proposed to be a promising therapeutic target for reducing,
if not eliminating, the risks of atherosclerosis and its
complications.Mediators of Inﬂammation 3
3. Structureof NF-κB/Rel Proteins
Although several homodimers and heterodimers are formed
by various members of the NF-κBp r o t e i nf a m i l y ,N F - κBi sa
term that is often used to describe the p50/p65 heterodimer,
which was the ﬁrst NF-κB dimer to be described [18, 52].
Indeed, p50 and p65 are the ﬁrst members of the NF-κB
gene family to be cloned and characterized [53–56]. As
shown in Figure 1, members of the NF-κB/Rel protein family
contain a highly conserved, N-terminal 300-amino acid
region known as the rel homology domain (RHD), which
mediatesdimerization,interactionwithIκBproteins,nuclear
translocation due to the presence of a nuclear localization
signal (NLS) within RHD, as well as binding to speciﬁc
sites within the promoters of target genes [10]. Although
the majority of NF-κB dimers are capable of transactivating
target genes, in vivo data demonstrated that some dimers
such as p50/p50 and p52/p52 homodimers can be inactive
or repressive [57–59]. The fact that p50 and p52 lack a C-
terminal region that is conserved in the majority of other
NF-κB proteins suggests that this region confers on NF-
κB proteins a transcriptional potential, and hence, it is
called the transactivation domain (TAD) [10]. Mutations
of important residues within TAD render activating NF-κB
dimers transcriptionally inactive [60]. RelB is a structurally
unique member of the NF-κB protein family in that it
contains a leucine zipper-like (LZ) region at its N-terminus,
which is required for its full transcriptional activity [61].
4. Regulation andActivityof
NF-κB/Rel Proteins
Under basal conditions, most NF-κB subunits are
sequestered in the cytosol, where they are constitutively
bound by members of the NF-κB inhibitor family of
proteins, mainly IκBα and IκBβ [54, 62]. However, diverse
stimuli including inﬂammatory cytokines, mitogens,
lipopolysaccharides, UV light, as well as bacterial and viral
pathogens can transduce a signal that ultimately results in
NF-κB liberation from its inhibitors, allowing NF-κB dimers
to translocate to the nucleus and become transcriptionally
active [9, 63, 64]. Except for RelB, all other NF-κB proteins
contain a protein kinase A (PKA) phosphorylation site
20–30 amino acids N-terminal of the NLS within RHD,
and phosphorylation of this site (S337 in p50 and S276 in
p65) seems to be essential for nuclear translocation [65, 66].
Moreover, phosphorylation of the PKA phosphorylation site
is important in protecting the transcriptional and DNA-
binding activities of active NF-κB dimers [67–70]. Studies
have shown that S276 in p65 is a major phosphorylation site
thatissubjecttocompartment-speciﬁcandstimulus-speciﬁc
phosphorylation by PKAc in the cytoplasm [70] and the
mitogen- and stress-activated protein kinase-1 (MSK1)
in the nucleus [71]. S276 phosphorylation is required for
optimal NF-κBa c t i v i t yi nd i ﬀerent cell types [71–73]. Other
important phosphorylation sites have been demonstrated to
be critical for optimal NF-κB transactivation potential. Such
sites include protein kinase C zeta-(PKCζ-) phosphorylated
S311 [74], casein kinase II (CKII)-phosphorylated S529 [75],
IKKα/β-phosphorylated S536 [76–78]. S536 in p65 has also
been shown to be subject to phosphorylation by other
kinases such as AKT/protein kinase B (PKB) [79, 80],
ribosomal S6 kinase 1 (RSK1) [81], TRAF family member-
associated (TANK)-binding kinase 1 (TBK1) [82, 83], and
IKKε [83] under certain circumstances.
Dimerization of NF-κB proteins is a prerequisite for NF-
κB to become transcriptionally active, and it is mediated
by speciﬁc motifs within RHDs of both members of NF-κB
dimers [9]. Studies have shown that the dimerization motifs
are located at the C-terminus of RHD, and mutation of crit-
ical residues within such motifs interferes with dimerization
[84–86].Site-directedmutagenesisexperimentsalsorevealed
the importance of certain residues within the dimerization
motifs in determining partner speciﬁcity [85–87]. Once
in the nucleus, active NF-κB dimers can bind to speciﬁc
DNA-binding sites, known as κB binding sites, within the
regulatoryregionsoftheirtargetgenes,leadingtogenetrans-
activation [10, 88]. The κB site has a conserved consensus
sequence of 10 nucleotides (GGGRNNYYCC where N is
any base, R is a purine, and Y is a pyrimidine), and slight
variations of the κB nucleotide sequence confer preference
to diﬀerent dimer combinations of NF-κB subunits [9, 88].
The N-terminus of RHD is known to be essential for DNA-
binding activity of NF-κB proteins [84, 89]. Although point
mutations of speciﬁc residues within this region do not
interfere with dimerization, they completely abrogate the
DNA-binding activity of NF-κB dimers [84, 90].
5. Inhibitorsof NF-κB
Work from Baltimore’s laboratory provided initial character-
ization of NF-κB coordinate regulation via physical interac-
tionwithitsinhibitors,membersoftheIκBfamilyofproteins
[8, 91]. The observation that nuclear NF-κB exists in an IκB-
unbound state indicated that IκB proteins can sequester NF-
κB in an inactive state in the cytosol. Initial characterization
of IκB proteins that associate with NF-κB led to the identiﬁ-
cationof37-kDaand43-kDaproteins,whicharenowknown
as IκBα and IκBβ,r e s p e c t i v e l y[ 92]. IκBα and IκBβ are the
most well-characterized members of the mammalian IκB
family of proteins, which contains a number of structurally
related proteins besides IκBα and IκBβ, including IκBγ1,
IκBγ2, IκBδ,I κBε,I κBR, IκBL, p100, p105, and Bcl-3 [9, 93].
Recently, a new member of the IκB protein family was
identiﬁed and named IκBζ [94]. Except for Bcl-3 and IκBζ,
which are constitutively localized in the nucleus [94, 95], all
other IκB proteins are localized in the cytosol [93]. Nuclear
localizationofBcl-3andIκBζ indicatesthattheseproteinsdo
notregulateNF-κBtranslocationintothenucleus,butrather,
they seem to be involved in regulating NF-κB transcriptional
and DNA-binding activities [94, 96–98].
6. Structureof IκBα andIκBβ
Structural organization of IκB proteins started to be uncov-
ered upon molecular cloning and characterization of the4 Mediators of Inﬂammation
IκBα gene (also known as MAD-3) in the early 1990s
[99, 100]. Now, it is clear that all IκB proteins known to
date possess three to seven centrally located, 30–33 amino
acid repeated sequences known as ankyrin (ANK) repeats
(also known as notch-related motifs, cell cycle repeats, and
cdc10/SW16 repeats) (Figure 1)[ 9, 93, 101]. These repeats
were initially identiﬁed in the SW16 protein expressed by
Saccharomyces cerevisiae [102]. Although the exact amino
acid sequences of ANK repeats found in diﬀerent IκBp r o -
teins can be distinct, ANK repeats have a consensus amino
acid sequence (XGXTPLHLAARXGHVEVVKLLLDXGADV-
NAXTK, where X can be any amino acid) [103, 104]. Even
within the same IκB protein, ANK repeats can be quite
distinct, and this is thought to be an important determinant
in the speciﬁcity and selectivity of the protein-protein inter-
action between IκBa n dN F - κB proteins [105]. The presence
of ANK repeats in IκB proteins renders them capable of
physically interacting with regions within the RHD of target
NF-κB dimers [106–108]. Additionally, IκBα,I κBβ,a n dI κBε
have N-terminal signal-receiving domain (SRD) containing
two highly conserved serine residues, which are known to be
importantphosphorylationsitesinvolvedintheregulationof
IκBf u n c t i o n[ 9, 93]. IκBα,I κBβ,I κBγ1, IκBγ2, IκBδ,I κBR,
IκBL,p100, andp105containaregionattheC-terminus that
is rich in proline, glutamate, aspartate, serine, and threonine
residues, and hence, it is called the PEST domain [9, 93]. The
PEST domain plays an important role in the inhibition of
NF-κB DNA-binding activity [109], as well as in IκBp r o t e i n
stability/turnover[52,110–113].AlthoughdeletionoftheN-
terminus and/or the C-terminus does not aﬀect IκBα ability
to interact with NF-κB dimers, point mutations of certain
residues within the N-terminus of IκBα render it resistant
to signal-induced phosphorylation and degradation [114–
117], while deletion of the C-terminus of IκBα interferes
with its ability to dissociate NF-κB from its DNA binding
sites [107, 109, 118]. Finally, two nuclear export signal (NES)
sequences have been identiﬁed in the N-terminus [119]a n d
C-terminus of IκBα [120]. Actually, the more conserved N-
terminal NES was shown to be necessary and suﬃcient for
IκBα nuclear export [119]. Eﬃcient nuclear translocation
and cytosolic relocalization (i.e., nuclear export) of IκBα is
ensured by the presence of NLS and NES, respectively.
7. Function of IκBαandIκBβ
Since IκBα and IκBβ are the best studied members of the
IκB protein family, special emphasis will be allotted to these
two molecules throughout this paper. Members of the IκB
protein family are constitutively and ubiquitously expressed
proteins that localize in the cytosol, except for Bcl-3 and
IκBζ which are primarily present in the nucleus [94, 95]. The
main function of IκB proteins is to inhibit NF-κBa c t i v i t y
when it is not required, and this happens via protein-protein
interaction that takes place between IκB proteins and NF-
κB dimers in the cytosol. IκBα and IκBβ interact via their
ANK repeats with the RHD of NF-κB dimerized proteins
in such a way that masks the positively charged regions of
the NLSs within the RHDs of NF-κB dimers [121, 122]. As
a result, NF-κB dimers are prevented from translocating to
the nucleus, and thus, they are kept in an inactive, IκB-
bound state in the cytosol [123–125]. Although IκB-NF-
κB interaction is mediated by ANK repeats of IκB proteins,
not all ANK repeats are involved in this interaction [107,
118, 126]. In an extensive site-directed mutagenesis study
performed to assess the signiﬁcance of every ANK repeat
within IκBα [107], a number of interesting ﬁndings were
revealed. First, the C-terminus of IκBα is required for the
protein to be functional, and thus, the ANK repeats are not
suﬃcient on their own to exert an inhibitory action towards
NF-κB. Second, lack of the third ANK repeat does not
impede IκBα inhibitory function, suggesting that this ANK
repeat is dispensable for IκBα inhibitory function. Third, the
only mutant forms of IκBα that are unable to inhibit NF-
κB activity are those that were incapable of interacting with
NF-κB. Another study suggests that the ﬁrst ANK repeat
of IκBα is mostly responsible for its inhibitory activity, and
substituting the ﬁrst ANK repeat in IκBβ with that of IκBα
signiﬁcantly enhances the former’s inhibitory activity [127].
It is evident that the ANK repeats and the C-terminal region
(i.e., PEST domain) of IκBα form a tertiary structure that
is capable of interacting with NF-κB proteins, and that such
interaction confers NF-κB transcriptional inactivity [107].
It is known that NF-κB is itself an upregulator of IκBα
and IκBβ, in which NF-κB activation via various and distinct
stimuli is usually followed by rapid induction of IκBα and
IκBβ expression [19, 52, 128] due to the presence of a κB
DNA-binding site within the IκBp r o m o t e r[ 129–131]. This
negative feedback regulatory loop sets a molecular switch
that ensures rapid, controlled, and transient activation of
target genes by NF-κB. Induced expression of IκBα allows
translocation of nascently synthesized IκBα into the nucleus,
where it binds to active NF-κB dimers that are bound to κB
sites within the promoters of their target genes. Interaction
between nuclear IκBα and active NF-κB dimers leads to
dissociation between NF-κB dimers and DNA, and it forces
a conformational change in IκBα that exposes the nuclear
export signal (NES), eventually leading to resequesterization
of IκBα and NF-κB dimers in the cytosol [92, 120, 132].
This highly complex, tightly regulated reciprocal regulatory
process involving NF-κBa n dI κB proteins confers the NF-κB
signaling pathway a central regulatory function in many key
biological events that requires transient, short-term NF-κB
activity.
8. Regulation of IκBαandIκBβ
There are at least two well-characterized signaling pathways
leading to NF-κB activation, classical and alternative, and
both rely on the catalytic activity of known IκB kinases
(IKKs) (Figure 2). The classical NF-κB signaling pathway is
typically triggered by a vast number of proinﬂammatory
cytokines (e.g., IL-1β and TNFα), viruses, and bacteria,
and hence, it leads to a coordinate inﬂammatory/immune
responseculminatingintheexpressionofmultiplecytokines,
chemokines, adhesion molecules, and proinﬂammatory
proteolytic enzymes [133, 134]. On the other hand, theMediators of Inﬂammation 5
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Figure 2:NF-κBSignalingPathway.Acartoonrepresentingthecascadeofbiochemicaleventsthatareinitiatedbyvariousstimuli,eventually
leading to NF-κB nuclear translocation and transcriptional activation. Recruitment of diﬀerent adaptor molecules to diﬀerent receptor
complexes coupled with activation of diﬀerent downstream kinases is shown. There are mainly two signaling pathways leading to NF-
κB activation, classical (also known as canonical) and alternative. The formation and activation of the IKK complex, which consists of
catalytically active kinases (e.g., IKKα,I K K β, and IKKγ) and noncatalytic regulatory proteins (e.g., NEMO and ELKS), is a universal event
in both signaling pathways. In the classical signaling pathway, ligand binding to a cell surface receptor leads to the recruitment of adaptor
proteins (e.g., TRAF6) to the receptor, leading to the recruitment of IKK complex and subsequent phosphorylation and degradation of the
IκB proteins. Unlike the classical signaling pathway, the alternative signaling pathway, which is normally triggered by non-proinﬂammatory
cytokines (e.g., LTβ, BAFF, and CD40L) as well as some viruses (e.g., HTLV and EBV), does not allow the recruitment of NEMO. Instead,
ligand binding to a cell surface receptor leads to the recruitment of NIK, which in turn phosphorylates and activates IKKα dimers. Typically,
theclassicalsignalingpathwayleadstotheactivationofNF-κBdimersconsistingofRelA,c-Rel,RelB,andp50,whilethealternativesignaling
pathway leads to the activation of NF-κB dimers consisting primarily of RelB and p52.
alternative NF-κB signaling pathway is normally triggered by
non-proinﬂammatory cytokines (e.g., lymphotoxin β (LTβ),
B-cell activating factor (BAFF), and CD40 ligand (CD40L))
as well as some viruses (e.g., human T-cell leukemia virus
(HTLV) and Epstein-Barr virus (EBV)) [133, 134]. The
alternative NF-κB signaling pathway is triggered to induce
the expression of genes whose products play fundamental
roles in the development and maintenance of secondary
lymphoid organs [133]. Unlike the classical pathway, the
alternative pathway is NEMO independent in that it does
not require the IκB kinase (IKK) complex, which contains
the scaﬀold protein NF-κB essential modulator (NEMO),
IKKα,I K K β,I K K γ, and other adaptor proteins [133–140].
Instead, the alternative pathway relies on the activity of the
NF-κBinducingkinase(NIK)thattransactivatesIKKα-IKKα
homodimers, which upon activation transduce a signal that
culminates in profound NF-κBa c t i v a t i o n[ 134]. In the next
sections, special attention will be paid to the classical NF-κB
signaling pathway.
9.BasalTurnover/Degradationof
IκBα andIκBβ
Besides signal-induced proteolytic degradation of IκBα and
IκBβ, these proteins have been shown to be susceptible
to degradation under basal, unstimulatory conditions. In
fact, IκBα and IκBβ have been shown to be constitutively
phosphorylated in absence of stimuli [67, 141], and speciﬁc
serine/threonine residues (S283,S 289,S 293,a n dT 291) within
the PEST domain of IκBα have been shown to be the target
ofconstitutivephosphorylationbyCKII[111,113,117,142].6 Mediators of Inﬂammation
Phosphorylation of the PEST domain renders IκBα suscep-
tible to degradation, indicating that the PEST domain is
essential for controlling IκBα intrinsic protein stability [111–
113]. Likewise, it was shown that the PEST domain of IκBβ
is required for its degradation [143]. Unlike signal-induced
degradation of IκBα, which required ubiquitination, basal
degradationofIκBαseemstobeubiquitinationindependent,
in which degradation of unubiquitinated IκBα is evident in
unstimulated cells in vitro [144]. This data is supported by
the observation that a mutant form of IκBα carrying lysine-
to-arginine substitutions at the two ubiquitination sites (K21
and K22) is as prone to basal degradation as the wild type
form (WT) of IκBα [145]. In other words, ubiquitination of
IκBα is a signal-induced event and is not required for basal
degradation of IκBα. However, the ubiquitin-independent
IκBα degradation pathway is proteasome dependent, since
proteasome inhibitors block basal, as well as signal-induced,
degradation of IκBα [144].
Until the emergence of a paper published by Phillips
and Ghosh in 1997 [146], the 26S proteasome-mediated
proteolysis pathway was the only known cellular process
responsible for basal and signal-induced degradation of
IκBα and IκBβ. However, the use of selective proteasome
inhibitors revealed the existence of a novel proteolysis
pathway that leads to IκBα and IκBβ degradation in an
ubiquitin-independent, proteasome-independent manner in
immature B cells [146, 147]. Indeed, such a novel pathway
was subsequently shown to be dependent on the presence
of free calcium, most likely imported from outside the
cell [145]. Further examination of this pathway revealed
that phosphorylation of the PEST domain of IκBα allows
it to bind to the calmodulin-like domain (CaMLD) of
the large subunit of the calcium-dependent thiol protease
complex, calpain [148, 149]. Interaction between IκBα and
calpain is followed by N-terminal cleavage and further
proteolysis of IκBα [148, 149]. These studies suggest that
IκBα and IκBβ can also be regulated by protease machiner-
ies other than the intrinsic, well-known 26S proteasome
complex.
10.Signal-InducedIκBα andIκBβ
Phosphorylation by the IKK Complex
In order for NF-κB to become activated, IκBα/β must
become phosphorylated at speciﬁc serine residues at the N-
terminus, followed by ubiquitination (not for IκBβ)a n d
proteolytic degradation of phosphorylated IκBα and IκBβ
in the cytosol. Phosphorylation and subsequent proteolytic
degradation of IκBα and IκBβ liberate NF-κB dimers, which
becomephosphorylated,translocatetothenucleus,andbind
to speciﬁc κB binding sites within the promoter/enhancer
regions of their target genes, leading to their transactivation.
Binding of TNFα to its receptor (TNFR1) is known to trigger
NF-κB activation through the classical pathway, leading to
TNF-induced cell death [150]. Under basal conditions, con-
stitutive activation of the TNF-induced cell death pathway is
prevented by the blocking potential of a protein called the
silencer of death domains (SODDs), which binds to TNFR1
and prevents downstream signal transduction [150]. Upon
TNFα-TNFR1 binding, SODD dissociates from TNFR1 and
this allows recruitment of adaptor molecules TNF receptor-
associated death domain (TRADD), receptor interacting
protein(RIP),andTNFRassociatedfactor2(TRAF2),which
bind to TNFR1 as a complex through TRADD. Sequential
recruitment of NIK and the IKK complex to the TRADD
complex bound to TNFR1 is mediated by TRAF2 [151, 152].
Stimulation signals triggered by LPS, IL-1β,a n dT N F α also
lead to the recruitment and activation of MEKK1 [153]. The
recruitedIKKcomplexalsocontainsanIκBkinaseregulatory
subunit called ELKS (glutamic acid, leucine, lysine, and
serine-rich protein), which allows IκBα recruitment and
interaction with the IKK complex at the membrane [154].
Although NEMO, IKKα,I K K β,I K K γ, and ELKS are the
main components of the cytoplasmic serine-protein-kinase
multi-subunit IKK complex, other proteins are identiﬁed as
essential elements of the complex [135–140, 155–157]. NIK
and MEKK1 are upstream upregulators of the IKK complex,
in which they phosphorylate and transactivate IKKα and
IKKβ within the complex [155, 158].
Membrane recruited IKK complex with catalytically
active IKKα and IKKβ is responsible for phosphorylating
two N-terminally located conserved serine residues in IκBα
and IκBβ (Ser32 and Ser36 in IκBα;S e r 19 and Ser23 in IκBβ)
[137, 159]. Interestingly, cell lines that lack NEMO display
severe defects in NF-κB activation and they are unrespon-
sive to a wide range of potent stimuli [139], indicating
that catalytically active IKKα and IKKβ are insuﬃcient in
phosphorylating IκBα and IκBβ in the absence of complex
formation. Although some studies have initially suggested
a major role of IKKα in IκBα and IκBβ phosphorylation
[135, 137, 156, 160, 161], a study demonstrated that
mutation of two serine residues within the activation loop of
IKKβ,b u tn o tI K K α, renders the IKK complex catalytically
inactive [162], indicating that IKKβ is the predominant
kinase component of the IKK complex. This observation is
supported by an experiment demonstrating that IKKα
−/−
cells display normal IKK activity towards IκBα and IκBβ
upon LPS, IL-1β,a n dT N F α treatment [163]. Moreover,
IKKβ
−/− mice resemble p65
−/− mice in that they suﬀer
from embryonic lethality due to severe liver apoptosis [164].
The apoptotic phenotype of IKKβ
−/− mice combined with
the observation that TNFα deﬁciency eliminate embryonic
lethality of p65
−/− mice [165] and that NF-κB mediates
TNFα-induced apoptosis [166] strongly suggest that IKKβ
catalytic activity is absolutely required for NF-κB activation.
Direct experimental evidence indicates that IKKβ
−/− embry-
onic stem cells and ﬁbroblasts display defective IKK activity
towards IκBα, and no NF-κBa c t i v i t y[ 164]. These ﬁndings
indicate that IKKα cannot compensate for IKKβ loss, and
that IKKβ is solely responsible for phosphorylating IκBα
and IκBβ in vivo. Interestingly, phosphorylation of S32/S36
and S19/S23 in IκBα and IκBβ, respectively, does not force
IκBα and IκBβ dissociation from their NF-κB dimer partners
in the cytosol [116, 167], but it renders them susceptible
to ubiquitination and subsequent proteolytic degradation
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11.Signal-InducedDegradation of
IκBα andIκBβ
Proteolysis, or proteolytic degradation, is a highly reg-
ulated cellular multistep process that involves enzymes
called proteases that are capable of hydrolyzing peptide
bonds within polypeptides that are usually ubiquitinated,
ultimately leading to protein degradation (Figure 3). Protein
ubiquitination and subsequent degradation were thought to
be molecular mechanisms undertaken by cells to eradicate
misfolded or defective proteins [172, 173]. Nevertheless, it
is well recognized that protein degradation is a process that
is not directed only against imperfect proteins, but also
against some fully functional proteins as a means to regulate
and control various key biological processes [10]. Cyclins,
proteins involved in the regulation of the cell cycle, are a
prime example of functional proteins that are regulated by
ubiquitination-dependent proteolytic degradation pathways
[174, 175].
It is evident that signal-induced phosphorylation of IκBα
and IκBβ must be followed by their degradation for NF-κB
transactivation potential to be manifested [167, 176–182].
The most compelling evidence indicating the necessity of
IκBα and IκBβ degradation for NF-κB activation came from
a study showing that treatment of stimulated cells with pro-
tease inhibitors does not eliminate phosphorylation of IκBα
and IκBβ, but protects NF-κB-IκBα and NF-κB-IκBβ cytoso-
liccomplexes,andthus,preventsNF-κBacti vation[143,167,
178, 181, 182]. Under stimulatory conditions, proteolytic
degradation of IκBα and IκBβ occurs via an ubiquitination-
and proteasome-dependent mechanism [169, 170].
The 26S proteasome is composed of a core protease,
known as the 20S proteasome, and the 19S regulatory
complex (RC), which is composed of at least 18 diﬀerent
subunits in two subcomplexes known as the lid and the
base [183]. The involvement of the 26S proteasome in
signal-induced NF-κB activation was originally signiﬁed
by studies demonstrating that treatment with selective
inhibitors of the 26S proteasome blocks NF-κBa c t i v a t i o n
[178, 184]. Subsequent to phosphorylation of the two
serine residues within the signal-induced kinase domain
of IκBα, multiple 76-amino acid ubiquitin polypeptides
covalently attach to the N-terminus of phosphorylated
IκBα, rendering IκB proteins susceptible to 26S proteasome-
dependent degradation [169, 170, 185, 186]. For IκBα,
ubiquitination primarily takes place on two adjacent lysine
residues (K21 and K22) in the N-terminus of the protein,
and mutation of these two lysine residues prevents IκBα
ubiquitination and subsequent proteolytic degradation [187,
188]. Indeed, conservative substitution of K21 and/or K22 by
arginine precludes not only ubiquitination, but also signal-
induced degradation of IκBα, ultimately preventing NF-κB
activation [187, 188]. During initial characterization of IκBβ
regulation, it was shown that treatment of cells with protease
inhibitors prevents IκBβ degradation [143], suggesting that
IκBβ may be under control of the ubiquitin-proteasome
machinery in a phosphorylation-dependent fashion, as in
IκBα. Indeed, site-directed mutagenesis of S19 and/or S23
renders IκBβ somewhat resistant to degradation [143].
Strikingly, however, alanine substitution of K9 has no eﬀect
on IκBβ degradation [143], indicating that ubiquitination
is not a prerequisite for IκBβ degradation. So, although
phosphorylation of the two, N-terminal conserved serine
residues is required for inducing IκBα and IκBβ degradation,
ubiquitination of the N-terminal lysine residues is required
for proteasome-dependent degradation of IκBα,b u tn o t
IκBβ. Interestingly, although the PEST domain of IκBα and
IκBβ is not required for S32/S36 and S19/S23 phosphorylation,
respectively, its deletion eliminates signal-induced degrada-
tion of IκBα [115, 117, 189–191]a n dI κBβ [192–194]. In
sum, for signal-induced NF-κB transactivation activity to
manifest, at least six main biochemical events must precede:
(1) phosphorylation of IκBα and IκBβ by the IKK complex,
(2) ubiquitination of phosphorylated IκBα, (3) proteasome-
mediated degradation of IκBα and IκBβ, (4) phosphoryla-
tion of NF-κB dimer, (5) nuclear translocation of NF-κB
dimer, and (6) NF-κB dimer-κB DNA interaction (Figure 3).
12. Regulation of NF-κBActivityvia
IκBα Sumoylation
Signal-induced IκBα phosphorylation and ubiquitination,
followed by its proteolytic degradation, are not the only
posttranslational modiﬁcations that target IκBα and regulate
NF-κB activity in cells. Sumoylation is deﬁned as process by
which a small ubiquitin-like modiﬁer (SUMO) (∼20kDa) is
covalentlyattachedtolysineresiduesontargetproteins[195–
197]. Similar to ubiquitination, the process of sumoylation
involves three enzymatic events that proceed sequentially,
ultimately culminating in SUMO conjugation to the protein
substrate by forming an isopeptide bond between SUMO
and the ε-amino group of a lysine side chain [198]. In 1998,
Desterro and colleagues have reported for the ﬁrst time the
existenceofamodiﬁed,slowermigratingformofIκBα[199].
This modiﬁed, slower migrating protein has been identiﬁed
as an SUMO-1-modiﬁed IκBα in several mammalian cells
including human embryonic kidney HEK 293 cells, monkey
COS-7, human T leukemic Jurkat cells, and HeLa cells [199].
Intriguingly, only a small fraction of total IκBα protein was
found to be modiﬁed by SUMO-1, and the degree of sumoy-
lation varied depending on the cell type with 50% being the
maximum proportion of sumoylated IκBα of the total IκBα
pool[199].Notably,nuclearlocalizationofIκBαwasdeemed
necessaryforitssumoylation[200].Signiﬁcantly,thesumoy-
latedformofIκBαwasfurthershowntobehighlyresistantto
signal-induced ubiquitination and subsequent proteasome-
mediated degradation compared to unmodiﬁed IκBα [199].
Desterro and colleagues went on to show that overexpression
of SUMO-1 inhibits signal-induced activation of NF-κB-
dependent transcription. In a later study, Guo and colleagues
have reported the identiﬁcation and cloning of SUMO-4,
which was proposed to conjugate with IκBα leading to NF-
κB downregulation [201]. Very recently, SUMO-4-mediated
downregulation of NF-κB was shown to be dependent on
modiﬁcation of IκBα by SUMO-4 [202]. Intriguingly, a κB
binding motif was also identiﬁed in SUMO-4 promoter, and
mutagenesis of this motif interfered with NF-κB-dependant8 Mediators of Inﬂammation
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Figure 3: Regulation of IκBα and IκBβ. A cartoon representing the
most critical intracellular events leading to NF-κB transcriptional
activation. Interaction between diverse ligands and their
receptors eventually leads to activation of the IKK complex,
which allows IκBα and IκBβ phosphorylation in the cytosol.
This phosphorylation step is followed by IκBα,b u tn o tI κBβ,
ubiquitination, and subsequently, IκBα and IκBβ are subjected
to proteolytic degradation. Once IκBα and IκBβ molecules are
degraded, NF-κB dimers are liberated, and they translocate to the
nucleussubsequenttounmaskingoftheirNLS.Onceinthenucleus,
NF-κB dimers bind to κB sites within the promoter/enhancer
regions of their target genes, driving gene transactivation.
transactivation of its target genes, suggesting a feedback
loop mechanism by which SUMO-4 regulates NF-κBa c t i vi ty
[202].
Unlike ubiquitination, which requires phosphorylation
at S32 and S36, phosphorylation at these sites interferes
with IκBα sumoylation [199], likely due to a conforma-
tional change that hinders SUMO-1 conjugation. Using
site-directed mutagenesis, it was also shown that SUMO-
1 conjugation requires K21 and K22 at the N-terminus of
IκBα;w i t hK 21 being the primary site for sumoylation
[199]. Strikingly, K21 and K22 are the target residues for
ubiquitination, providing a plausible explanation for the
prolongedstabilityofsumoylatedIκBαcomparedtounmod-
iﬁed IκBα. This observation also suggests that SUMO-1 and
ubiquitin molecules compete for these residues to regulate
IκBα function, and thus, NF-κBa c t i v i t y .M o r e o v e r ,m a n y
hydrolases that can potentially cleave the bond between
SUMO-1 and its targeted lysine residue on the substrate,
hence known as desumoylating enzymes, have been iden-
tiﬁed [203–206]. Hence, controlling the balance between
sumoylation and desumoylation of IκBα may serve as a
mechanism underlying the regulation of NF-κBa c t i v i t y .
Sumoylation of IκBα may be a physiologically signiﬁcant
anti-inﬂammatory mechanism undertaken by cells to sup-
presslethalinﬂammatoryresponsesviaconvertingIκBαpro-
teins from their degradation-susceptible, unmodiﬁed form
into a degradation-resistant, sumoylated one. Interestingly,
in an in vitro study, it was demonstrated that epithelial cells
exposed to increasing periods of hypoxia; a condition that
triggers a wide range of inﬂammatory events, responded
by increasing the proportion of SUMO-1-bound IκBα and
cAMP-response element-binding protein (CREB) [207]; a
transcription factor that induced the expression of various
proinﬂammatory cytokines. Consistently, induced hypoxia
led to a signiﬁcant increase in transcriptional expression
of SUMO-1 [207]. Very recently, it was demonstrated that
adenosine signaling mediates SUMO-1 modiﬁcation of IκBα
during hypoxia [208] .S e v e r a ls t u d i e sh a v ed e m o n s t r a t e da
tight link between SUMO-4 polymorphism and susceptibil-
ity to type-I diabetes [201, 209, 210]. However, this correla-
tion between SUMO-4 polymorphism and susceptibility to
type-I diabetes seems to be more prevailing among Asian
populations compared to Caucasians. Wang and colleagues
have recently reviewed the correlation between SUMO-4
polymorphism and type-I diabetes, and they provided some
insights to explain the discrepancy noted among diﬀerent
populations and the mechanisms through which SUMO4
contributes to the pathogenesis of type-I diabetes [211].
SUMO-4 polymorphism seems to have no correlation with
susceptibility of other inﬂammatory conditions including
Grave’s disease [212], rheumatoid arthritis [213–215], and
systemic lupus erythematosus [216]. Finally, it is conceivable
that modulation of IκBα sumoylation may be utilized as a
mechanismtoaggravateoralleviatethesymptomsofvarious
NF-κB-driven inﬂammatory conditions.
It is important to mention that other proteins involved
in NF-κB signaling pathways are also subject to sumoyla-
tion. For example, sumoylation on K277 and K309 residues
of NEMO by SUMO-1 conjugation has been shown to
mediate NF-κB activation by genotoxic stress [217]. In fact,
regulation of NF-κB activity by NEMO sumoylation occurs
under a variety of other stress conditions including oxidative
stress, ethanol exposure, heat shock, and electric shock
[218]. Details regarding the mechanisms involved in NEMO
sumoylation were revealed by a recent study demonstrating
that NEMO sumoylation is mediated by protein inhibitor
of activated STATy (PIASy), which seems to preferentially
stimulate site-selective modiﬁcation of NEMO by SUMO-1,
but not SUMO-2 or SUMO-3, in vitro [219].
13.Cross-TalkbetweenGlucocorticoid
Receptor (GR) and NF-κB Signaling
Although signal-induced posttranslational modiﬁcation
of IκBs by phosphorylation, ubiquitination, sumoylation,
and proteolytic degradation serves as the central molecularMediators of Inﬂammation 9
mechanism by which NF-κB signaling is regulated, several
IκB-independent mechanisms have been proposed as
eﬀective, alternative cellular events that are crucial in
the regulation of NF-κBa c t i v i t y .S u c hI κB-independent
mechanisms seem to be critical in the alternative,
noncanonical NF-κB signaling pathway and they occur
via post-translational modiﬁcation of various proteins,
other than IκBs, that are critically involved in NF-κB
signaling. Like IκBs, some members of the Rel family of
proteins can be subject to signal-induced post-translational
modiﬁcations that ultimately lead to modulation of NF-κB
activity [134, 220, 221]. Signal-induced phosphorylation
of RelA, which was ﬁrst documented about ﬁfteen years
ago [67, 141], is by far the most extensively studied post-
translational modiﬁcation in the regulation of NF-κB
signaling (for review, refer to [134, 220, 221]). Similarly,
post-translational modiﬁcations of RelB [222, 223], c-Rel
[224–229], and p50 [67, 230] have also been documented as
IκB-independent regulatory mechanisms involved in NF-κB
signaling.
Moreover, other IκB-independent mechanisms involv-
ing a complex interplay between NF-κB and other NF-
κB-unrelated proteins have been recently revealed. The
glucocorticoid receptor (GR) is a prime example of such
regulatory proteins that are critically implicated in the
control of NF-κB signaling pathways. GR is a hormone-
dependent transcription factor belonging to the nuclear
receptorsuperfamily,anditiscriticallyinvolvedinmediating
the immunosuppressive functions of glucocorticoids by
repressing the expression of major cytokines. Although
the exact molecular mechanisms underlying the repression
function of GR on NF-κB activity are not fully understood,
experimentalevidencesuggeststhatitisprimarilytheligand-
induced physical interaction between GR and DNA-bound
NF-κB subunits (RelA and p50) that ultimately inhibits NF-
κBa c t i v i t y[ 231–236]. The regulation of NF-κB activity via
the interaction between GR and NF-κB subunits seems to
be independent on GR DNA binding and homodimerization
[236–238]. Although there is a consensus among researchers
that the GR-mediated regulation of NF-κB signaling takes
place in the nucleus, it was proposed that ligand-induced
activation of GR by glucocorticoids may regulate NF-κB
signaling in the cytoplasm by increasing IκBα protein level
in HeLa cells, monocytic cells, and T cells [239, 240].
However, induction of IκBα seems to be cell type-speciﬁc
mechanism underlying GR-mediated repression of NF-κB
activity since glucocorticoid treatment caused inhibition
of NF-κB activity without any detectable change in IκBα
expression in endothelial cells [241] or epithelial cells [242,
243]. In an in vitro study involving human pulmonary
epithelial A549 cells, monkey COS-1 cells, and human breast
cancer T47D cells, it was shown that GR-mediated inhibition
of NF-κB activity occurs via a dual mechanism involving
both protein-protein interaction between GR and NF-κB
subunits and induction of IκBα expression; with the former
mechanism being predominant in NF-κB regulation [244].
Moreover, it seems that GR-mediated repression of NF-κB
activity via IκBα induction is not only cell type-speciﬁc,
but it is also dependent on the type of ligand, the NF-κB
target gene, the presence of certain cofactors, the status of
chromatin, and probably other conditions [221, 242, 245].
Noteworthy,othermechanismsunderlyingGR-mediated
repression of NF-κB activity have been proposed. For
example, GR activation was shown to be associated with
suppression of histone acetylase (HAT) activity via inhibited
recruitment of large coactivator complexes containing HAT
regulatory proteins such as CREB-binding protein (CBP)
and p300 [246]. Moreover, GR activation was shown to
cause induced expression of histone deacetylase 2 (HDAC2)
accompanied by recruitment of GR to NF-κBt a r g e tg e n e s
leading to their transrepression [246]. It seems that the
concentration of glucocorticoids is one determining factor
incontrollingthebalancebetweenGR-mediatedsuppression
of HAT activity and induction of HDAC activity leading
to modulated NF-κBa c t i v i t y[ 246]. Interestingly, GR itself
is subject to deacetylation by HDAC2, which leads to GR
nuclear translocation and physical interaction with NF-κB
subunits [247]. It is also documented that induced histone
methylation,ratherthansuppressedhistoneacetylation,may
serve as a mechanism that underlies GR-mediated repression
of NF-κB functions [248, 249]. Additionally, experimental
evidence revealed that attenuation of GR-mediated transre-
pression of its target genes is accompanied by recruitment
of potent corepressors such as nuclear receptor corepressor
(NCoR) and silencing mediator of retinoid and thyroid
hormone receptor (SMRT) [250–253]. Furthermore, it was
proposed that GR interferes with NF-κB-dependent serine
phosphorylation of the C-terminal domain of RNA poly-
merase II leading to suppressed expression of NF-κBt a r g e t
genes [235]. These ﬁndings suggest that GR activation may
repress NF-κB activity without inﬂuencing NF-κBD N A
binding potential. Consistent with this proposal, treatment
ofasthmaticpatientswithinhaledglucocorticoidssuppresses
inﬂammation via inhibition of NF-κB-mediated expression
of inﬂammatory mediators with no detectable reduction in
NF-κB DNA binding ability [254]. Together, these ﬁndings
strongly suggest that GR can modulate NF-κBa c t i v i t yi n
the nucleus by regulating several key events including NF-κB
DNA binding, HAT and/or HDAC expression, coactivator(s)
and/or corepressor(s) recruitment, as well as RNA poly-
merase II-induced transactivation of NF-κBt a r g e tg e n e s .
Finally, glucocorticoids may serve as inhibitors of NF-κB
activity via their ability to modulate the activity of proteins
involved in the mitogen-activated protein kinase (MAPK)
pathways including c-jun N-terminal kinase (JNK), p38, and
MAP kinase phosphatase-1 (MKP-1), all of which can cross-
talk and modulate NF-κB activity, and thus, inﬂammatory
responses [255–263].
14. AEBP1 Is aMultifunctionalProtein
Adipocyte enhancer-binding protein-1 (AEBP1) is a ubiq-
uitously expressed protein whose expression seems to be
the highest in adipose tissue, liver, lung, spleen, and
brain [264]. Recently, AEBP1 was shown to be abundantly
expressed in primary macrophages as well as macrophage
cell lines [265–267]. AEBP1 shares a remarkable amino acid10 Mediators of Inﬂammation
sequence homology with two members of the regulatory
carboxypeptidase family of enzymes, CPX1 and CPX2, all of
which contain N-terminal discoidin-like domain (DLD) and
homologous central carboxypeptidase (CP) domain [268].
Unlike CPX1 and CPX2, which are catalytically inactive
[269, 270], AEBP1 functions as an active carboxypeptidase
capable of catalyzing hydrolysis of arginine and lysine in
hippuryl-arg and hippuryl-lys synthetic carboxypeptidase B
(CPB) substrates, respectively [271, 272]. Studies from Ro’s
laboratory have demonstrated that deletion of residues 429
to 460 in the CP domain, which encompasses the active site,
renders AEBP1 catalytically inactive [271]. Moreover, the
carboxypeptidase activity of AEBP1 has been shown to be
responsivetocarboxypeptidaseactivatorsandinhibitors,and
that DNA binding enhances AEBP1 hydrolytic activity [272],
indicating that AEBP1 functions as an active carboxypepti-
dase.
AEBP1 is highly expressed in preadipocytes, and its
expression persists during the ﬁrst stages of adipogenesis
[271, 273]. However, AEBP1 levels drop dramatically as
preadipocytes diﬀerentiate into mature adipocytes, and
AEBP1 expression is completely abolished in terminally
diﬀerentiated, nonproliferative adipocytes [264, 271, 273].
Because of the altered expression pattern of AEBP1 dur-
ing adipogenesis, AEBP1 was suspected to play a neg-
ative regulatory role in adipose P2 (aP2) expression in
preadipocytes. Indeed, in vitro studies have demonstrated
that AEBP1 speciﬁcally binds adipocyte enhancer-1 (AE-1)
DNA sequence [271], and transcriptionally represses aP2 in
3T3-L1 preadipocytes and other cell lines [271, 273, 274].
TranscriptionalrepressionofaP2byAEBP1isphysiologically
signiﬁcant since targeted over-expression of AEBP1 in adi-
posetissuecausesdiet-inducedobesityinmice[275].AEBP1
seems to induce massive obesity in mice with targeted,
tissue-speciﬁc overexpression of AEBP1 (AEBP1TG mice) by
inducingadipocyteproliferationinvivo,leadingtoadipocyte
hyperplasia in white adipose tissue [275]. In contrast,
AEBP1-deﬁcient mice (AEBP1
−/− mice) display 25% reduc-
tionintotalbodyweightduetosigniﬁcantlyreducedfatpads
caused by enhanced apoptosis and impaired survival signal
[276]. Indeed, AEBP1TG preadipocytes display augmented
proliferation [273, 275], while AEBP1
−/− preadipocytes
exhibit a defective proliferative potential in vitro [276].
MAPK pathways are a network of serine/threonine
kinases and dual-speciﬁcity kinases, whose function is impli-
cated in various key biological processes in the cell includ-
ing proliferation, inﬂammation, and tumorigenesis [277–
280]. Kinases involved in MAPK pathways include JNK1/2,
extracellular signal-regulated kinases 1 and 2 (ERK1/2), and
other MAP kinases (e.g., MEK, MEKK, and MEKKK). In
vitro and in vivo experimental studies revealed that AEBP1
physically interacts with ERK1/2 via its DLD [273]. This
protein-proteininteractioniscriticalforMAPKactivitysince
it leads to protection of ERK1/2 from dephosphorylation
by its speciﬁc phosphatase (MKP-3), leading to sustained
activation of ERK1/2 [273]. AEBP1 inhibits diﬀerentiation
of preadipocytes into mature adipocytes, thus impeding
adipogenesis, by means of enhancing ERK1/2 activity in
preadipocytes [273].
Recently, AEBP1 was shown to be a critical regulator of
macrophage cholesterol homeostasis, foam cell formation,
and macrophage inﬂammatory responsiveness [265]. In fact,
AEBP1 was shown to manifest its proinﬂammatory eﬀects
by promoting NF-κB activity via impeding the inhibitory
function of IκBα in macrophages, an event that seems to
be dependent on AEBP1-IκBα physical interaction [266].
Most recently, experimental evidence indicates that AEBP1
mediates LPS-induced foam cell formation by virtue of its
ability to directly suppress peroxisome proliferator-activated
receptor γ1( P P A R γ1 )a n dl i v e rXr e c e p t o rα (LXRα)a c t i vi t y
in macrophages, suggesting that AEBP1 may play a critical
regulatory role in bacterial infection-induced atherosclerosis
[267].
15.DLD MediatesAEBP1-IκBαInteraction
The N-terminus of AEBP1 contains DLD that is remarkably
homologous to discoidin, a lectin expressed in the slime
mold Dictyostelium discoideum [281], and hence the name.
In Dictyostelium discoideum, discoidin has been shown to
be crucial for proper cell aggregation and migration [282]
as well as protein-protein interaction [283, 284]. Indeed,
DLD of AEBP1 was found to be required for protein-protein
interaction between AEBP1 and MAPK [273]. Similarly, it
was shown that AEBP1 is capable of physically interacting
with IκBα by means of its DLD, whose deletion eliminated
AEBP1-IκBα interaction [266]. It is worth mentioning that
despite the structural similarities between IκBα and IκBβ,
co-immunoprecipitation experiments suggest that AEBP1
is capable of interacting with IκBα,b u tn o tI κBβ,i n
macrophages [266]. Analysis of IκBα-IκBβ amino acid
sequence alignment reveals that there are three main struc-
tural diﬀerences between IκBα and IκBβ (Figure 4). First,
the ﬁrst 12 amino acid residues in IκBα are absent in IκBβ.
Second, there is a 41-amino acid stretch located between
the third and forth ANK repeat of IκBβ that is not present
in IκBα. Third, there is an 18-amino acid stretch at the C-
terminus of IκBβ t h a ti sa b s e n ti nI κBα.B a s e do ns e q u e n c e
analysis, it is conceivable that either the presence of the ﬁrst
12 amino acid residues in IκBα is required for interaction
with AEBP1 or that the presence of the extra-amino
acid stretches in IκBβ allows the formation of a tertiary
structure that does not permit protein-protein interaction
with AEBP1. It is also conceivable that the extra-amino acid
stretches in IκBβ somehow mask the region, or domain, that
is necessary for protein-protein interaction with AEBP1. We
are currently attempting to map the exact region of IκBα
thatmediatesprotein-proteininteractionwithAEBP1,which
will shed more light on the diﬀerential ability of AEBP1 to
regulate IκBα and IκBβ functions. Further investigation of
the AEBP1-interacting region of IκBα will shed more light
on how AEBP1 is capable of diﬀerentially regulating IκBα
and IκBβ functions in vivo. Although modulation of IκBα
expression has been previously shown to be a mechanism
explaining altered NF-κBa c t i v i t y[ 285–287], the data we
have recently demonstrated is the ﬁrst of its kind to propose
a molecular mechanism behind modulated NF-κBa c t i v i t y
by which IκBα protein stability is altered via protein-proteinMediators of Inﬂammation 11
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Figure 4: Amino Acid Sequence Comparison between IκBα and IκBβ. (a) Alignment of amino acid sequences of mouse IκBα and IκBβ
is shown. The six highly conserved ANK repeats in both proteins are highlighted in grey, yellow, green, red, pink, and blue, respectively.
(b) A cartoon illustrating a comparison of the slightly diﬀerent structural domain organizations of mouse IκBα and IκBβ proteins. The
signal-induced kinase domain, six ANK repeats, and PEST domain of each protein are shown.
interaction and is independent of alterations in IKK complex
kinetic activity [266].
Since about 50% of AEBP1 protein population exists in
the nucleus [266, 288], and since newly synthesized IκBα is
knowntotranslocatetothenucleustobindDNA-boundNF-
κB dimers and resequester them into the cytosol [64], it is
possible that AEBP1 and IκBα interact in the nucleus. This
is an interesting possibility since AEBP1-IκBα interaction
in the nucleus can interfere with the ability of nuclear
IκBα to bind to its target, DNA-bound NF-κB dimers,
leading to sustained NF-κB-driven transactivation of target
genes (e.g., proinﬂammatory genes). Thus, by virtue of its
cytosolic/nuclear localization and its ability to bind IκBα,
it is reasonable to propose that AEBP1 can impede IκBα
inhibitoryfunctionstowardsNF-κBbothatthecytosolicand
nuclear levels.
Noteworthy, DLD has been identiﬁed in several extracel-
lular and intracellular proteins including discoidin domain
receptor tyrosine kinase (DDR) [283], the blood coagulation
cofactors V and VIII [289], milk-fat globule proteins [290],
muskelin [284], retinoschisin [291], and developmental
endothelial locus-1 (Del-1) [292]. It would be of great
interest to assess whether such DLD-containing proteins
have the potential to physically interact with IκBα,a sd o e s
AEBP1. Such assessment coupled with careful analysis of the
amino acid variations among the DLD sequences of these
proteins will assist in mapping the exact amino acid stretch
within DLD that mediates interaction with IκBα.12 Mediators of Inﬂammation
16.DLD MediatesAEBP1 Protein-Protein
Interactionwith Other Proteins
DLD has been suggested to mediate cell-cell adhesion
[293], protein self-association [284], and protein-protein
interaction [283, 284]. In fact, protein-protein interaction
between AEBP1 and MAPK in the cytosol, which prolongs
MAPK activation by protecting it from dephosphorylation
by its speciﬁc phosphatase (MKP-3, also known as PYST1),
has been shown to be mediated by DLD of AEBP1 [273].
Similarly, AEBP1 was shown to be capable of physically
interacting with cytosolic IκBα via its DLD, whose deletion
eliminates AEBP1-IκBα protein-protein interaction [266].
So, these ﬁndings further support a role of DLD in protein-
protein interaction in mammalian systems. Furthermore,
these ﬁndings underscore the importance of DLD in medi-
ating very critical functions undertaken by AEBP1 to control
key biological processes in the cell. Intriguingly, we propose
that the presence of DLD creates a molecular competition
between MAPK and IκBα in the cytosol to bind to AEBP1.
This proposal is interesting given that sustained MAPK
activation and IκBα proteolytic degradation followed by NF-
κB activation culminate in diverse biological outcomes in
diﬀerentcelltypes.Althoughthemolecularmechanismsthat
signal AEBP1 to interact predominantly with MAPK or IκBα
are unknown, it is conceivable that AEBP1 can be utilized
by the cell as an on/oﬀ switch to promote or inhibit MAPK
and NF-κB activities via balancing AEBP1 protein-protein
interaction with MAPK and IκBα.
17. AEBP1 andNF-κB: A PositiveRelationship
Since its initial identiﬁcation by Sen and Baltimore about
two decades ago [294], NF-κB has been the focus of
many researchers in an attempt to understand the various
molecular mechanisms involved in inﬂammatory diseases
and cancer. Modulation of NF-κB activity can result in many
abnormal cellular processes and diseases including asthma,
arthritis, atherosclerosis, obesity, and various types of can-
cers[2–7].Recently,wehaveprovidedexperimentalevidence
establishing a positive relationship between AEBP1 expres-
sion and NF-κBa c t i v i t yi nm a c r o p h a g e s[ 266]. Nuclear p65
protein level was shown to be barely detectable in AEBP1
−/−
macrophages, compared to AEBP1+/+ counterparts [266].
Consistently, electrophoretic mobility gel shift assay clearly
illustrates that ablation of AEBP1 expression in macrophages
correlates with inhibited NF-κB DNA-binding activity [266].
This positive relationship seems to be a consequence of
a negative relationship between AEBP1 expression and
IκBα protein stability in macrophages. Interestingly, AEBP1
was shown to promote IκBα phosphorylation followed by
its proteolytic degradation, liberating the NF-κB subunits,
which translocate into the nucleus and become transcrip-
tionally active [266]. Furthermore, this negative regulation
imposed by AEBP1 on IκBα function in the cytosol seems
to be mediated by protein-protein interaction that requires
DLD of AEBP1, as conﬁrmed by co-immunoprecipitation
analysis [266]. Consistent with the proposal that AEBP1-
IκBα protein-protein interaction, which is mediated by
DLD, provokes destabilization of IκBα shortening its half-
life, the N-terminus deletion (ΔN) and carboxypeptidase
(CP) mutant forms of AEBP1, which are devoid of DLD,
have no inﬂuence on IκBα protein stability, unlike AEBP1
derivatives retaining DLD [266]. Importantly, in contrast
to the WT form of AEBP1, ΔN and CP mutant forms
possessmarginalornoupregulatoryfunctiontowardsNF-κB
activity [266], conﬁrming that AEBP1-IκBα interaction is a
keybiologicaleventthatiscrucialforAEBP1-mediatedIκBα-
induced degradation and subsequent NF-κB up-regulation
in macrophages.
It is known that alteration of IKKβ kinetic activity
ultimately leads to modulation of IκBα phosphorylation and
proteolytic degradation [164]. Given that AEBP1 regulates
IκBα phosphorylation status and its proteolytic degradation,
one mayspeculatethatAEBP1is capableof modulating IκBα
function in macrophages by means of altering the kinetic
potential of IKKβ. However, this possibility was ruled out
by in vitro kinase assays demonstrating that IKKβ kinetic
activity against a bacterially expressed GST-IκBα (aa 1-54)
fusion protein is comparable in AEBP1+/+ and AEBP1
−/−
macrophages under both basal and LPS-stimulatory condi-
tions [266]. In addition, it was shown that AEBP1 is not
a component of the IKK complex nor it inﬂuences the
composition of the IKK complex in macrophages [266].
In a recent report, we have hypothesized that the positive
regulatory role that AEBP1 imposes on NF-κBa c t i v i t ym a y
n o tb em a c r o p h a g es p e c i ﬁ c[ 266]. In fact, abrogation of NF-
κB activity has been shown to cause embryonic lethality
due to liver apoptosis [25, 26, 164]. If AEBP1-mediated
positive regulation of NF-κB is a universal process that
takes place in cells and tissues other than macrophages (e.g.,
liver), one would expect that AEBP1
−/− embryos may suﬀer
from liver apoptosis that is life-threatening. Although NF-
κB activity has not been evaluated in AEBP1
−/− hepatocytes,
it is fascinating that AEBP1
−/− mice suﬀer from about 50%
embryonic lethality [276]. Hence, severe diminishment of
NF-κB activity, which can potentially lead to liver apoptosis,
that is caused by AEBP1 deﬁciency may serve as a molecular
mechanism underlying embryonic lethality in AEBP1
−/−
mice. Interestingly, our recent ﬁndings reveal that the levels
of the apoptotic markers p-STAT3 and cleaved caspase-
3 are signiﬁcantly higher in the livers of AEBP1
−/− mice
compared to control mice (unpublished), suggesting that
AEBP1 plays an antiapoptotic role in vivo. Consistent with
its ability to promote NF-κB activity in various cell types,
preliminary ﬁndings suggest that AEBP1 also promotes
NF-κB activity in mammary gland tissue, in which NF-
κB activity is signiﬁcantly enhanced and diminished in
the mammary gland tissues obtained from mice that over-
express and lack AEBP1, respectively (unpublished). In sum,
AEBP1-mediated promotion of NF-κBa c t i v i t ys e e m st ob ea
regulatory event that occurs in various cells and tissues.
18. Differential Regulation of IκBαandIκBβ:
A Possible Role for AEBP1?
Despite their structural homology, individual IκBp r o -
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diﬀerential ability and preference to associate with and
inhibit variouscombinationsofNF-κBdimersinthecytosol.
For example, both IκBα and IκBβ preferentially interact with
and inhibit the activity of NF-κB dimers containing p50,
p65, and c-Rel [54, 123, 295], IκBγ prefers p50 homodimers
and p50/p65 heterodimers [296], IκBε prefers p65 and c-
Rel homo- and heterodimers [297], and Bcl-3 prefers p50
and p52 homodimers [95, 298]; whereas p100 and p105
seem to bind to almost all possible dimer combinations of
NF-κB proteins [89, 299]. It is also known that diﬀerent
NF-κB dimers display diﬀerential intrinsic preference with
regard to DNA binding speciﬁcity [88, 300], and this
DNA binding speciﬁcity confers distinct NF-κB dimers a
diﬀerential transactivation potential towards a diverse set of
genes [301].
Additionally, IκBα and IκBβ are known to be diﬀer-
entially regulated in various cell types and under several
stimulatory conditions [143, 295]. Although both IκBα
and IκBβ become ubiquitinated upon phosphorylation, the
two lysine residues (Lys21 and Lys22) at the N-terminus of
IκBα are required for ubiquitination; whereas the lysine
residue (Lys9) at the N-terminus of IκBβ is not required
for ubiquitination [143]. In addition, several studies have
demonstrated that while IκBα is subject to rapid degradation
upon cell stimulation by various stimuli including LPS, IL-
1β,T N F α,a n dP M Ai nm o s tc e l lt y p e s ,I κBβ degradation
cannot be induced except by very few potent stimuli such
as LPS and IL-1β in certain cell types and it tends to be
a relatively slow process [147, 295]. However, other studies
have shown that S19/S23-phosphorylated IκBβ is subject to
degradation induced by PMA or TNFα treatment [143, 302].
The slower kinetics associated with IκBβ degradation has
been suggested to be probably due to the slower rate of
IκBβ phosphorylation by the IKK complex, which seems to
favor IκBα as a more eﬃcient substrate [192]. So, depending
on the potency of signals, IκBβ may or may not become
subject to phosphorylation and subsequent degradation
[10]. The diﬀerential ability of IKKβ to phosphorylate IκBα
and IκBβ has been suggested as a mechanism to explain
the diﬀerential proteolytic degradation kinetics of IκBα and
IκBα [159]. Here, it can be argued that AEBP1, by virtue
of its diﬀerential ability to interact with IκBα,b u tn o t
IκBβ, may play a determining role in making IκBα more
susceptiblethanIκBβtosignal-inducedphosphorylationand
subsequent degradation. Hence, AEBP1 physical interaction
with IκBα,b u tn o tI κBβ, has been proposed to serve as
a mechanism that may elucidate the diﬀerential regulatory
functions exhibited by these two molecules in vitro and
in vivo [266].
Since the PEST domain plays a critical role in IκB
protein turnover/stability [52, 110, 143], it is arguable that
the function of this domain is diﬀerentially regulated in
IκBα and IκBβ, thus leading to their diﬀerential regulation.
However, studies have shown that deletion or mutations
within the PEST domain confer resistance to signal-induced
degradationforbothIκBα[110,115,117,189–191]andIκBβ
[143, 192–194]. In light of these results, understanding the
role of PEST domain does not seem to help in explaining
the diﬀerential regulation imposed on IκBα and IκBβ.I n
addition, while the two N-terminal lysine residues (K21 and
K22)o fI κBα are known to be ubiquitination sites that are
required for signal-induced degradation of IκBα [187, 188],
the only N-terminal lysine residue (K9)i nI κBβ does not
seem to be an exclusive ubiquitination site, and its mutation
has no eﬀect on signal-induced degradation of IκBβ [143].
Moreover, it was shown that IκBβ is phosphorylated on
Ser19 and Ser23 in unstimulated cells; whereas Ser32 and Ser36
phosphorylation in IκBα is only signal induced [143].
In sum, the diﬀerential speciﬁcity of IκB/NF-κB interac-
tion combined with the diﬀerential transactivation potential
of diﬀerent NF-κB dimers may explain how diﬀerential
regulation of distinct IκB proteins can lead to diﬀerential
regulation of NF-κB dimer activity, and thus, diﬀerential
expression control of discrete genes. However, due to the
remarkable similarities between IκBα and IκBβ in terms of
their structure and NF-κB dimer speciﬁcity, understanding
the molecular mechanisms behind the diﬀerential regulatory
functions undertaken by these two molecules in diﬀerent
cell types and under diﬀerent conditions has proven to be a
tremendous challenge, and so far, a crystal-clear explanation
of such diﬀerential regulation of these two molecules is still
lacking.
19.AEBP1-IκBα Interaction Leads to IκBα
Degradation:Unknown Mechanism
To date, two pathways have been suggested as molecular
mechanisms responsible for IκBα proteolytic degradation.
First, upon stimulation, IκBα is thought to be degraded via
a classical, signal-induced proteasome-dependent pathway
that involves the 26S proteasome [170]. Second, in vitro
studies using immature B cells have demonstrated that
IκBα can be subject to constitutive proteasome-independent,
Ca++-dependent degradation under basal conditions [145].
It was also shown that constitutive phosphorylation of ser-
ine/threonine residues within the C-terminal PEST domain
of IκBα by CKII is required for IκBα turnover [111–
113]. Also, accumulation of free IκBα in the cytosol
triggers its rapid degradation through a phosphorylation,
ubiquitination-independent proteasome-dependent path-
way [144]. The exact molecular mechanism(s) underly-
ing the regulatory role of AEBP1 towards IκBα activity
is not yet identiﬁed. However, we have questioned the
molecular mechanisms by which AEBP1-IκBα interaction
leads to IκBα phosphorylation and subsequent proteolytic
degradation, and three speculative points regarding such
molecular mechanisms were oﬀered [266]. First, AEBP1-
IκBα interaction could cause a conformational change
in the latter rendering it more susceptible to Ser32/Ser36
phosphorylation and degradation via the ubiquitination-
dependent proteasome-dependent pathway. Second, IκBα-
bound AEBP1 could serve as a recruiting scaﬀold protein
that facilitates recruitment of the constitutive proteasome-
independent Ca++-dependent proteolytic or ubiquitination-
independentproteasome-dependentmachineries.Third,itis
possible that AEBP1-bound IκBα is more prone to consti-
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the PEST domain, inducing its proteasome-dependent pro-
teolytic degradation. Here, we speculate that AEBP1 may
also serve as a “bridge” that brings IκBα in proximity to
IKKα/β in the cytosol, forcing IκBα phosphorylation and
subsequentproteolyticdegradation.Inaddition,itispossible
that AEBP1 somehow enhances the catalytic activity of an
“unknown” kinase that can potentially phosphorylate S32
and S36 in IκBα. Moreover, one may speculate that AEBP1
interferes with an “unknown” phosphatase that exercises
its catalytic activity on S32/S36-phosphorylated IκBα in the
cytosol. Finally, AEBP1 interaction with IκBα may protect
the latter from sumoylation, favoring its ubiquitination and
subsequent proteolytic degradation. Examination of these
possibilities may shed light on the exact molecular mech-
anism undertaken by AEBP1 to hamper IκBα inhibitory
function towards NF-κB.
20.AEBP1-MediatedNF-κB Upregulation
Is Independent of PPARγ1an d
LXRα Modulation
Experimental evidence suggesting that PPARγ1a n dL X R α
play anti-inﬂammatory roles is overwhelming. PPARγ and
LXR ligands suppress inﬂammation by interfering with
the NF-κB, AP-1, and STAT signaling pathways [303–
312]. PPARγ1a n dL X R α repression by AEBP1 serves as a
mechanism that satisfactorily explains the proinﬂammatory
propertiesexhibitedbyAEBP1inmacrophages.SinceAEBP1
represses PPARγ1a n dL X R α transcriptional activity in
macrophages [265, 267], active PPARγ1a n dL X R α interfere
with NF-κBa c t i v i t y[ 303, 304, 307, 313], and AEBP1
enhances NF-κB activity, it is reasonable to suggest that
PPARγ1a n dL X R α transcriptional repression by AEBP1
may contribute to AEBP1-mediated NF-κB up-regulation
in macrophages. However, this eﬀect may be negligible
since deletion of DLD, which does not inﬂuence the ability
of AEBP1 to repress PPARγ1o rL X R α [265], completely
eliminates the ability of AEBP1 to up-regulate NF-κB
activity [266]. In agreement, deletion of the C-terminus of
AEBP1, which completely eliminates the ability of AEBP1
to repress PPARγ1o rL X R α [265], does not interfere with
the ability of AEBP1 to up-regulate NF-κBa c t i v i t y[ 266].
Additionally, Glass and colleagues have shown that neither
treatment of RAW 264.7 macrophages with PPARγ ligand
nor PPARγ1 overexpression in absence of its ligand had any
anti-inﬂammatory eﬀects [304]. Rather, PPARγ-mediated
anti-inﬂammatory eﬀects are only observed when PPARγ1i s
over-expressed and ligand activated [143]. Similarly, LXRα-
mediated anti-inﬂammatory eﬀects can only be observed
in the presence of LXR ligands and under LPS-stimulatory
conditions [307]. However, AEBP1 was shown to enhance
NF-κB activity in macrophages expressing endogenous
PPARγ1a n dL X R α in the absence of PPARγ or LXR ligands
under both basal and LPS-stimulatory conditions [266].
Collectively, we conclude that co-ordinate AEBP1-mediated
IκBα proteolytic degradation and subsequent NF-κBu p -
regulation is independent of AEBP1-mediated PPARγ1a n d
LXRα repression in macrophages.
21.PotentialRole ofAEBP1 in
SepticShockSyndrome
Septic shock syndrome is a very serious medical condition
thatcanleadtofailureofmanybodyorgans,eventuallycaus-
ing death. Septic shock is caused by an exaggerated immune
response against the LPS component of various Gram-
negative bacteria via TLR signaling [320, 321]. Very recently,
LPS was shown to signiﬁcantly induce AEBP1 expression in
macrophages, and that LPS-induced down-regulation of the
pivotal anti-inﬂammatory mediators PPARγ1a n dL X R α is
largely mediated by AEBP1 [267]. Given the role that AEBP1
plays in LPS signaling in macrophages, and given AEBP1 role
in inducing macrophage proinﬂammatory responsiveness
[265] via promoting NF-κBa c t i v i t yi nm a c r o p h a g e s[ 266], it
is conceivable that AEBP1
−/− mice may be resistant to LPS-
induced septic shock and Gram-negative bacterial infection-
induced atherosclerosis. In contrast, AEBP1TG mice with
targeted overexpression of AEBP1 in adipose tissue and
macrophages [275] are expected to be more susceptible
to LPS-induced septic shock and Gram-negative bacterial
infection-induced atherosclerosis compared to their WT
counterparts. It would be very intriguing to investigate the
susceptibility of AEBP1
−/− and AEBP1TG mice to develop
septic shock syndrome upon administration of pathogenic
Gram-negative bacteria such as C. pneumonia.
22.Other IκBα-InteractingProteinsand
Modulation of NF-κBA c ti vi ty
Recently, very few studies have proposed that protein-
protein interactions involving IκBα may serve as a molecular
mechanism explaining the potential of some proteins to
modulate NF-κB activity in vitro and in vivo. Besides
NF-κB subunits, only a handful of proteins have been
shown to physically interact with IκBα using yeast two-
hybrid system or co-immunoprecipitation experiments. The
X protein of hepatitis B virus (HBV) has been shown
to physically interact with IκBα,b u tn o tI κBβ, and this
interaction leads to sustained NF-κB activation following
TNFα treatment [314]. Mutagenesis analysis revealed that
the 249-253 amino acid sequence towards the C-terminus
of IκBα is critical for protein-protein interaction between
Xp r o t e i na n dI κBα [314]. Human β-arrestin2, a cytosolic
protein that is expressed predominantly in the spleen and
neuronal tissue, has been shown to directly interact with
IκBα leading to inhibited phosphorylation and degradation
of IκBα, ultimately leading to NF-κB down-regulation [315].
Theﬁrst60aminoacidswithintheN-terminusofβ-arrestin2
comprise the IκBα interacting region, and the C-terminal
domain (40 amino acids) of IκBα contributes to the β-
arrestin2binding[315].UsingGSTfusionproteinpull-down
assays, the poxvirus and zinc ﬁnger (POZ) domain at the N-
terminus of FBI-1 (factor that binds to the inducer of short
transcripts of human immunodeﬁciency virus-1), a ubiqui-
tously expressed nuclear protein, has been shown to mediate
protein-protein interaction between FBI-1 and IκBα [316].
Additionally, ChlaDub1 is a deubiquitinating protease fromMediators of Inﬂammation 15
Table 1: IκBα-Interacting Proteins and Impact on NF-κBA c t i v i t y .
IκBα-Interacting
Protein
Species IκBα-Interacting
Region
Interaction Region of
IκBα
Impact on NF-κB
Activity
Reference
Xp r o t e i n Hepatitis B Virus Unknown C-terminus
(aa 249-253)
↑ [314]
β-arrestin2 Homo sapiens N-terminus (aa 1-60) C-terminus
(aa 276-317)
↓ [315]
FBI-1 Homo sapiens POZ domain (aa
24-131) Unknown ↑ [316]
AEBP1 Mus musculus DLD (aa 1-166) Unknown ↑ [266]
ChlaDub1 Chlamydia trachomatis Unknown Unknown ↓ [317]
GRK5 Homo sapiens RH domain (aa
50–176)
N-terminus
(aa 1–58)
↓ [318]
N
pro Classical Swine Fever Virus Unknown C-terminus
(aa 213–317)
↔ [319]
Chlamydia trachomatis that has been shown to physically
interact with IκBα, leading to impaired ubiquitination and
proteolytic degradation of IκBα and blocked NF-κBa c t i v a -
tionintransfectedHeLaandHEK293Ncells[317].Similarly,
human G protein-coupled receptor kinase 5 (GRK5), a
protein that is highly expressed in the heart, placenta, lung
and skeletal muscle, has been shown to interact with IκBα
in BAEC and HEK293 cells [318]. GRK5-IκBα interaction
has been shown to enhance nuclear accumulation of IκBα,
ultimately causing diminished NF-κB-driven transcription
and NF-κB DNA binding [318]. The regulator of gene
protein signaling homology domain of GRK5 (RH) and
the N-terminal domain of IκBα have been identiﬁed as the
regions involved in GRK5-IκBα interaction [318]. Finally,
a yeast two-hybrid screen of a human library and co-
immunoprecipitation experiments have recently revealed
that N-terminal protease (Npro) of classical swine fever virus
(CSFV), a protein that is localized in the cytosolic and
nuclearcompartments,physicallyinteractswithIκBαleading
to transient nuclear accumulation of pIκBα in the infected
porcine kidney cell line PK-15 [319]. Yet, NF-κBa c t i v a t i o n
does not seem to be signiﬁcantly aﬀected in PK-15 cells that
were stably transfected with Npro [319]. It seems that the C-
terminal (aa 213-317) region of IκBα is essential for Npro-
IκBα interaction [319].
To date, however, AEBP1 is the only protein that
was shown to be an interacting partner of IκBα in
macrophages, and AEBP1-IκBα interaction seems to be
physiologically signiﬁcant with regard to NF-κBt r a n s a c t i -
vation and macrophage inﬂammatory responsiveness [266].
In an attempt to identify a consensus sequence that may
be responsible of mediating protein-protein interaction
between the IκBα-interacting proteins mentioned above and
IκBα, the amino acid sequences of the IκBα-interacting
regions within these proteins were compared. Amino acid
sequence analysis revealed that there is no obvious consensus
sequence or considerable similarities within the identiﬁed
IκBα-interacting regions of AEBP1, FBI-1, β-arrestin2, and
GRK5. Since the exact region of IκBα that mediates phys-
ical interaction between IκBα and these proteins is either
diﬀerent or unknown, it is diﬃcult to search for other
potential, yet unknown, IκBα-interacting protein based on
amino acid sequence similarities. The so-far identiﬁed IκBα-
interacting proteins and the domains/sequences involved in
such interactions are outlined in Table 1.
23. Conclusion
NF-κB signaling is critically involved in various biological
processes that are crucial for cell growth and survival. The
role that NF-κB plays in inﬂammatory reactions cannot be
underestimated. By virtue of its ability to act as a direct
interacting partner of IκBα via its DLD, AEBP1 exerts
a potent upregulatory function toward NF-κBa c t i v i t yi n
macrophages. Hence, AEBP1 manifests itself as a critical
modulator of inﬂammatory responses. Finally, we anticipate
that AEBP1 may serve as a likely molecular target towards
the development of novel therapeutic strategies for the
prevention or treatment of various inﬂammatory disorders
such as atherosclerosis and septic shock syndrome.
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HAT: Histone acetylase
HDAC: Histone deacetylase
ICAM-1: Intracellular adhesion molecule-1
IL: Interleukin
IFNγ:I n t e r f e r o n γ
IκB: Inhibitor of NF-κB
IKK: IκB kinase
iNOS: Inducible nitric oxide synthase
IRAK: Interleukin 1 receptor-associated kinase
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MAPKKK)
MKP: MAP kinase phosphatase
MMP: Matrix metalloproteinase
NCoR: Nuclear receptor co-repressor
NEMO: NF-κB essential modulator
NES: Nuclear export signal
NF-κB: Nuclear factor kappa B
NIK: NF-κB inducing kinase
NLS: Nuclear localization signal
Npro: N-terminal protease
oxLDL: Oxidized low density lipoprotein
PEST: Proline-glutamate/aspartate-serine-
threonine
PIASy: Protein inhibitor of activated STATy
PKA: Protein kinase A
PKB/AKT: Protein kinase B
PKC: Protein kinase C
PMA: Phorbol-12-myristate-13-acetate
POZ: Poxvirus and zinc ﬁnger domain
PPARγ1: Peroxisome proliferator-activated
receptor γ1
RHD: Rel homology domain
RIP: Receptor interacting protein
SMRT: Silencing mediator of retinoid and
thyroid hormone receptor
STAT: Signal transducer and activator of
transcription
SUMO: Small ubiquitin-like modiﬁer
TAD: Transactivation domain
TNFα: Tumor necrosis factor α
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TRAF: TNFR associated factor
VCAM-1: Vascular cell adhesion molecule-1
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